Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 7 years of Other Operating Expenses data on file, last reported at $111.6 million in Q2 2026.

• Quarterly Other Operating Expenses rose 57.19% year-over-year to $111.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $382.6 million (up 52.71% YoY) and the FY2025 annual result came in at $307.2 million, up 62.36% from the prior year.
• Other Operating Expenses advanced to $111.6 million in Q2 2026, from $96.4 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $111.6 million in Q2 2026 to a low of $8.7 million in Q2 2022.
• A 5-year average of $46.9 million and a median of $36.9 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 317.78% — and 2023, when it advanced 22.86%.
• Tracing KNSA's Other Operating Expenses over 5 years: stood at $14.2 million in 2022, then surged by 86.36% to $26.5 million in 2023, then surged by 149.16% to $66.1 million in 2024, then soared by 37.66% to $91.0 million in 2025, then rose by 22.72% to $111.6 million in 2026.
• The last three Other Operating Expenses figures came in at $111.6 million (Q2 2026), $96.4 million (Q1 2026), and $91.0 million (Q4 2025), per Business Quant data.